SEC61G promotes colorectal cancer progression by regulating cytosolic Ca2+ concentration
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-025-02259-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Satoshi Higuchi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Beppu, Oita, 874-0838, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, SEC Translocation Channels, Calcium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Intracellular calcium (Ca2+) signaling regulates key cancer processes. Research findings suggest that the SEC61 complex, involved in protein translocation, contributes to calcium leakage from the endoplasmic reticulum. However, the mechanism by which SEC61 Translocon Subunit Gamma (SEC61G), a component of this complex, influences colorectal cancer (CRC) progression remains unclear. METHODS: Bioinformatics analysis was performed using The Cancer Genome Atlas data sets to identify candidate genes on chromosome 7p, examine their association with DNA copy number amplification. In addition, SEC61G expression in CRC cells and tissues was validated using reverse-transcription quantitative polymerase chain reaction and immunohistochemistry. Moreover, in vitro and in vivo experiments were performed to investigate the effects of SEC61G overexpression and knockdown on CRC cell proliferation. Furthermore, publicly available single-cell RNA sequencing (scRNA-seq) and spatial transcriptome sequencing (ST-seq) data were used to validate the role of SEC61G in CRC. RESULTS: SEC61G was significantly upregulated in CRC tissues and was correlated with poor prognosis in patients with CRC. SEC61G overexpression enhanced cell proliferation and activated the EGFR pathway, promoting cell cycle progression from the G1 to S phase. In addition, SEC61G overexpression increased cytosolic Ca2+ levels, which activated EGFR signaling via calmodulin. Moreover, analyses of scRNA-seq and ST-seq data confirmed that SEC61G expression was higher in tumor epithelial cells and that it was co-expressed with EGFR pathway-related genes. CONCLUSIONS: SEC61G promotes CRC progression by regulating cytosolic Ca2+ concentration, EGFR activation, and cell cycle progression, highlighting its potential as a prognostic biomarker and therapeutic target in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Beppu, Oita, 874-0838, Japan.
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Department of Breast and Endocrine Surgery, Kochi University, Kochi, Japan.
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Beppu, Oita, 874-0838, Japan. mimori.koshi.791@m.kyushu-u.ac.jp.
Zitieren
APA
Higuchi, S., Otsu, H., Masuda, T., Hashimoto, M., Nakano, Y., Hosoda, K., Hirose, K., Ikehara, T., Ofuchi, T., Tsuda, Y., Yonemura, Y., Uemura, M., Eguchi, H., Doki, Y., & Mimori, K. (2025). SEC61G promotes colorectal cancer progression by regulating cytosolic Ca2+ concentration. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02259-3
Vancouver
Higuchi S, Otsu H, Masuda T, Hashimoto M, Nakano Y, Hosoda K, et al. SEC61G promotes colorectal cancer progression by regulating cytosolic Ca2+ concentration. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02259-3
BibTeX
@article{Higuchi2025,
author = {Higuchi, Satoshi and Otsu, Hajime and Masuda, Takaaki and Hashimoto, Masahiro and Nakano, Yusuke and Hosoda, Kiyotaka and Hirose, Kosuke and Ikehara, Tomohiko and Ofuchi, Takashi and Tsuda, Yasuo and Yonemura, Yusuke and Uemura, Mamoru and Eguchi, Hidetoshi and Doki, Yuichiro and Mimori, Koshi},
title = {SEC61G promotes colorectal cancer progression by regulating cytosolic Ca2+ concentration},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-025-02259-3}
}
EUVIMED